Repare Therapeutics Inc

Repare Therapeutics — Investor Presentation (May 2024)

47 slides from Repare Therapeutics's investor presentation, May 7, 2024

  1. Slide 1: Insight that enriches. Precision that empowers. Corporate Presentation May 2024

    Insight that enriches. Precision that empowers. Corporate Presentation May 2024

  2. Slide 2: Disclaimer

    Disclaimer Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," “plans,” “poten

  3. Slide 3: Differentiated, proprietary clinical pipeline

    3 3 Differentiated, proprietary clinical pipeline Lunresertib: First-in-class oral PKMYT1 inhibitor (Phase 1/2) Camonsertib: ATR inhibitor (Phase 1/2) RP-1664: First-in-class selective PLK4 inhibitor (Phase 1) Developing Next-Generation Precision Oncology Medicines Multiple clinical catalysts expect

  4. Slide 4: Targeting the untargetable through synthetic lethality

    Targeting the untargetable through synthetic lethality Specifically targeting and disrupting genes essential for cancer cell survival SNIPRx identifies and targets necessary genes to induce synthetic lethality Highly targeted & tumor-type agnostic approach Exploiting cancer cell genomic instability,

  5. Slide 5: Expanding pipeline of precision oncology therapeutics

    Expanding pipeline of precision oncology therapeutics PROGRAM TUMOR LESION DRUG TARGET PRECLINICAL PHASE 1 PHASE 2 PHASE 3 RIGHTS Lunresertib (RP-6306) CCNE1, FBXW7 + others PKMYT1 Camonsertib (RP-3500) ATM + 16 STEP2 lesions ATR RP-1664 TRIM37-high PLK4 RP-3467 BRCA1/2 Polθ ATPase SNIPRx® Platform

  6. Slide 6: Proven experience in drug discovery and development

    Proven experience in drug discovery and development Leadership Team Scientific Founders Steve Forte, CPA Chief Financial Officer Michael Zinda, PhD Chief Scientific Officer Maria Koehler MD, PhD Chief Medical Officer Cameron Black, PhD Head of Discovery Philip Herman Chief Commercial, Portfolio Deve

  7. Slide 7: Lunresertib (RP-6306)

    Lunresertib (RP-6306)

  8. Slide 8: Lunresertib: First-in-class, oral, small molecule, PKMYT1 inhibitor

    Lunresertib: First-in-class, oral, small molecule, PKMYT1 inhibitor Large, genomically defined potential addressable patient population of ~90k 50% RECIST response in camonsertib combination in gynecological tumors Repare discovered synthetic lethality of PKMYT1 inhibition Initially identified CCNE1

  9. Slide 9: Large, genomically defined potential patient population

    Large, genomically defined potential patient population Top New Advanced Tumor Cases (US+UK/EU4) Top Tumors (New Advanced Cases, US+UK/EU4) Tumor Type Prevalence of Genes of Interest Eligible Patients Uterine 7,000 Ovarian 6,300 Stomach 9,000 Colorectal 24,500 Bladder 6,200 Cervical 1,300 Esophageal

  10. Slide 10: Evolving broad trial program: sponsored and collaborative

    Evolving broad trial program: sponsored and collaborative PPP2R1A FBXW7 Recurrent solid tumors Key inclusion criteria: CCNE1 amplification or inactivating mutations Determine RP2D dose / schedule Progress to late-stage trials MAGNETIC: + Gemcitabine MYTHIC: + Camonsertib; + Debio 0123 (Wee1 inhibito

  11. Slide 11: Lunresertib: MYTHIC Preliminary Phase Trial Results

    Lunresertib: MYTHIC Preliminary Phase 1 Trial Results (M1: Monotherapy) (M2: Camonsertib Combination Therapy) OR, overall response; CBR, clinical benefit rate. MONOTHERAPY Safe, well tolerated and anti-tumor activity observed (N=67) Recommended Phase 2 dose: 80 mg twice daily in intermittent schedul

  12. Slide 12: Key updates since ENA 2023; registrational decision on track

    Key updates since ENA 2023; registrational decision on track Registrational decision on track in gyn expansions in Q4 2024 Continuing trends of patient response and benefit Grade 3 anemia reduced from 45% to 25% at RP2D with updated dosing 2 weeks on / 1 week off for patients with low Hg, otherwise

  13. Slide 13: Lun + cam responses across tumor types and genotypes

    Lun + cam responses across tumor types and genotypes * One response evaluable patient became uPR and four patients had responses confirmed after the Sept. 5, 2023 cutoff, data as of Oct. 6, 2023. Relevant patient tumor co-mutations †BRCA1 rearrangement and ‡BRCA2 biallelic loss. +Treatment ongoing.

  14. Slide 14: Frequent and deep tumor reductions observed with lun + cam

    *Efficacy evaluable patients only (≥1 post-baseline tumor assessment). Other tumor types include cervical (n=1), esophageal (n=1), GI (n=1), liver (n=1), lung (n=3), melanoma (n=1), osteosarcoma (n=1), pancreatic (n=2), and upper GI (n=1). CBR: overall response or time on treatment ≥ 16 wk w/o progr

  15. Slide 15: Gynecologic cancers: meaningful tumor reductions, durable benefit

    * Gynecologic cancers: ovarian, endometrial, and cervical cancers. Data represent the efficacy evaluable population (≥1 post-baseline tumor assessment). CBR, clinical benefit rate; OR, overall response based on RECIST or GCIG CA-125 response; MRR, molecular response rate; PR, partial response; RECIS

  16. Slide 16: Significant improvement in anemia observed with updated dosing

    Significant improvement in anemia observed with updated dosing Selected hematologic TRAEs, n (%) All Grades Gr3 Gr4 All Grades Gr3 Gr4 Anemia 13 (65.0) 9 (45.0) 0 29 (65.9) 11 (25.0) 0 Leukopenia 3 (15.0) 0 0 9 (20.5) 3 (6.8) 0 Neutropenia 3 (15.0) 2 (10.0) 0 7 (15.9) 5 (11.4) 0 Thrombocytopenia 0 0

  17. Slide 17: TRAEs in ≥10% of patients

    TRAEs in ≥10% of patients, n (%) All Grades Gr3 Gr4 Nausea/Vomiting 34 (52.3) 0 0 Rasha 26 (40.0) 1 (1.5) 0 Fatigue 18 (27.7) 1 (1.5) 0 Stomatitis 18 (27.7) 4 (6.2) 0 Decreased appetite 13 (20.0) 0 0 Diarrhea 10 (15.4) 0 0 Headache 7 (10.8) 0 0 Constipation 5 (7.7) 0 0 a Data as of March 2024; all p

  18. Slide 18: Lun + FOLFIRI combination promising

    Lun + FOLFIRI combination promising Source: Clarivate-Decision Resources Group, No added heme tox observed to FOLFIRI alone MINOTAUR demonstrating overall favorable tolerability and early signal in CRC and other GI tumors Favorable tolerability: lunresertib given continuously daily (QD), demonstrati

  19. Slide 19: First clinical trial inhibiting both PKMYT1 and WEE1

    First clinical trial inhibiting both PKMYT1 and WEE1 Combination synergistically eradicates ovarian cancer cells and organoid models at a low doses… Strong preclinical evidence of PKMYT1 + WEE1 inhibitor combination potential; Ph1/1b now enrolling Benada et al., NAR Cancer, 2023. …drives tumor regre

  20. Slide 20: Platinum-resistant ovarian cancer (PROC) market opportunity

    Platinum-resistant ovarian cancer (PROC) market opportunity 1 Chemo+Bevacizumab vs Chemo (AURELIA); Source: Bevacizumab FDA Label 2 Mirvetuximab vs Chemo (MIRASOL); Source: Mirvetuximab FDA Label, ASCO 2023. Mirvetuximab is approved for ~1/3 of PROC patients who are folate receptor positive. 3 Eligi

  21. Slide 21: Endometrial cancer market opportunity

    Endometrial cancer market opportunity 1 Lenvatinib/Pembrolizumab vs Single Agent Chemo (KEYNOTE-775); Source: Lenvatinib FDA Label 2 Ixabepilone vs Paclitaxel or Doxorubicin; McMeekin S. Gynecologic Oncology 2015 https://doi.org/10.1016/j.ygyno.2015.04.026 3 Eligible Patients in US and EU4/UK Based

  22. Slide 22: Metastatic CRC is a large market opportunity for MINOTAUR

    Metastatic CRC is a large market opportunity for MINOTAUR 1 FOLFIRI+Aflibercept vs FOLFIRI (VELOUR); Source: Aflibercept FDA Label 2 FOLFIRI+Ramucirumab vs FOLFIRI (RAISE); Source: Ramucirumab FDA Label, Lancet 2015 3 Napabucasin+FOLFIRI vs FOLFIRI+Bevacizumab (CanStem303C); Source: Shah M. Clinical

  23. Slide 23: Camonsertib (RP-3500)

    Camonsertib (RP-3500) R=PARE THERAPEUTICS

  24. Slide 24: Camonsertib: Potential best-in-class ATR inhibitor

    Camonsertib: Potential best-in-class ATR inhibitor Durable antitumor activity in combination with PARPi; meaningful clinical benefit observed in ovarian cancer Global development and commercialization rights wholly-owned by Repare - Rapid monotherapy signal confirmation in NSCLC Proof of concept est

  25. Slide 25: Potential across significant additional patient populations

    Potential across significant additional patient populations Top 10 Tumor Types* with Highest Prevalence of ATM Deficiency Top 10 Tumor Types* with Highest Prevalence of ATM Deficiency or STEP2 Genomic Alterations * TCGA; Not weighted for tumor prevalence

  26. Slide 26: Updated camonsertib monotherapy data in ATMm tumors

    Updated camonsertib monotherapy data in ATMm tumors Updated data continues to support ATR-ATM synthetic lethality thesis across various tumor types and genotypes 114 total efficacy evaluable patients treated at 3 efficacious dose levels 36 patients enrolled with ATM alterations 4 with responses and

  27. Slide 27: Camonsertib: rapid monotherapy signal confirmation in NSCLC

    Camonsertib: rapid monotherapy signal confirmation in NSCLC >12 months durability observed in >20% of patients with ATMm tumors treated with camonsertib monotherapy ATMm NSCLC (~4% of NSCLC) an attractive opportunity Camonsertib monotherapy signal potentially offers rapid and cost-efficient path to

  28. Slide 28: Camonsertib NSCLC market opportunity

    Camonsertib NSCLC market opportunity 1 Atezolizumab vs Chemo (OAK); Source: Atezolizumab FDA Label 2 Ramucirumab+Chemo vs Chemo (REVEL); Source: Ramucirumab FDA Label 3 Eligible Patients in US and EU4/UK Based On Company Estimates from TCGA and GENIE, 2L+ (2L - 5L) 2nd Line+ Therapy Single Agent Che

  29. Slide 29: RP-1664

    RP-1664

  30. Slide 30: Actively enrolling in solid tumors and neuroblastoma

    Actively enrolling in solid tumors and neuroblastoma RP-1664 First-in-class, oral PLK4 inhibitor ~63K addressable patient population with limited treatment options; potential across multiple tumor types Strong, dose-dependent anti-tumor activity observed as monotherapy across preclinical models High

  31. Slide 31: High prevalence in patient populations with limited treatment options

    High prevalence in patient populations with limited treatment options *Based on estimated number of pts available for 1st line treatment in the advanced setting (CancerMPact®, Patient Metrics, 2022; accessed 8/18/23) and lesion prevalence (TCGA; GENIE-Neuroblastoma Only). 1 Represents only gene ampl

  32. Slide 32: Compelling synthetic lethal rationale for targeting PLK4

    Compelling synthetic lethal rationale for targeting PLK4 Biomarker-driven patient selection hypothesis for development of oral PLK4i for TRIM37-high tumors Centrosomes use centrioles and pericentriolar material (PCM) for mitotic spindle formation Polo-Like Kinase 4 (PLK4) required for centriole crea

  33. Slide 33: Potential first-in-class oral PLK4 inhibitor

    Potential first-in-class oral PLK4 inhibitor Key Parameter RP-1664 In vitro PLK4 Enzyme IC50 1 nM PLK4 cell binding IC50 3 nM Cell proliferation in MCF7 / T47D (TRIM37 amp) EC50 51 / 17 nM Cell-base selectivity vs AurA, AurB >2000-fold Kinome screen at 90x PLK4 IC50 8/280 kinases >50% inh ADME Human

  34. Slide 34: Robust monotherapy efficacy across solid tumor PDX/CDX models

    Robust monotherapy efficacy across solid tumor PDX/CDX models Breast (Triple Negative) CDX Monotherapy drives tumor stasis to regression in TRIM37-high models Breast (ER positive) PDX NSCLC PDX

  35. Slide 35: Highly efficacious as monotherapy in neuroblastoma models

    Highly efficacious as monotherapy in neuroblastoma models Neuroblastoma PDX and CDX models (all TRIM37-high) conducted at Children’s Hospital of Philadelphia demonstrate deep and prolonged monotherapy regressions in 5 of 6 evaluable models COG-N-424X Felix COG-N-421 COG-N-453x NBSD Ebc1 *J Maris and

  36. Slide 36: RP-1664 Phase 1/2 monotherapy clinical development plan

    RP-1664 Phase 1/2 monotherapy clinical development plan Phase 1 Trial Adult solid tumors TRIM37-high High grade pediatric neuroblastoma Phase 1b Expansion Phase 1/2 Investigation Adult and adolescent patients with solid tumors TRIM37-high & additional biomarkers Goal: Recommended Phase 2 dose & safe

  37. Slide 37: RP-3467

    RP-3467

  38. Slide 38: RP-3467 capable of complete regressions and synergies in PARPi resistance models

    RP-3467 capable of complete regressions and synergies in PARPi resistance preclinical models RP-3467 Potential best-in-class Polθ ATPase inhibitor FPI in 2H 2024 Global market segments comprise $16 billion in PARP inhibitors, RLT, and chemotherapy Demonstrates compelling potential for combination ef

  39. Slide 39: RP-3467 clinical plan: multiple potential Phase 1/2 trials

    RP-3467 clinical plan: multiple potential Phase 1/2 trials Initiation expected in H2 2024 Goal: PK, safety and RP2D Phase 1 Trial PARPi combination – PARP1/2 or PARP1 Deep/durable complete responses preclinically, with no additional toxicity RLT combination Survival benefit preclinically in unselect

  40. Slide 40: Profound, durable synergy observed with PARP inhibition

    Profound, durable synergy observed with PARP inhibition HCT116 BRCA2 -/- Body Weight Deep/durable complete regressions observed across a wide dose range and well tolerated olaparib olaparib olaparib olaparib

  41. Slide 41: Polθ: uniquely promising therapeutic target

    Polθ: uniquely promising therapeutic target Polθ is a unique multifunctional DNA polymerase with ATP-dependent DNA helicase activity Required for microhomology-mediated end joining (MMEJ), a key mechanism of double-strand DNA break repair Uniquely active to repair double-strand DNA breaks during mit

  42. Slide 42: Target profile: potent, tolerable, capable of complete regressions

    Target profile: potent, tolerable, capable of complete regressions Highly potent, selective and orally bioavailable Polθ ATPase inhibitor; clean PanLabs safety pharmacology screen RP-3467 demonstrated complete regressions in BRCA1/2 null PDX models, also synergy in a PARPi resistance model Parameter

  43. Slide 43: Addressing unmet need in critical patient populations

    Addressing unmet need in critical patient populations PARP-naïve and PARP-treated (Treated Patients US+UK/EU4)* Top Tumors (New Advanced Cases, US+UK/EU4) Tumor type Prevalence of gene of interest PARP-naïve opportunity (1L) PARP-resistant opportunity (2L) Ovarian 7,700 3,500 Castrate-Resistant Pros

  44. Slide 44: Multiple potential market opportunities for near term milestones

    Multiple potential market opportunities for near term milestones Expansion Opportunities to 1L Near Term Opportunity Lun + FOLFIRI 2L+ CRC (FBXW7) Camonsertib 2L+ NSCLC (ATM) Lun + Cam 2L+ Endometrial (CCNE1/FBXW7/PPP2R1A) Lun + Cam 2L+ PROC (CCNE1) Drug Treated Patients Per Year1 (2024 Estimate; US

  45. Slide 45: Recent and expected milestones

    Lunresertib + Debio 0123 combination data Camonsertib monotherapy data in NSCLC Initiate first pivotal trial for lun+cam in 2025 Camonsertib monotherapy expansion to NSCLC in TRESR RP-3467 Ph1 clinical trial initiation Lunresertib + camonsertib expansion cohort data in ovarian and endometrial in Q4

  46. Slide 46: Differentiated, proprietary clinical pipeline

    46 46 Differentiated, proprietary clinical pipeline Lunresertib: First-in-class oral PKMYT1 inhibitor (Phase 1/2) Camonsertib: ATR inhibitor (Phase 1/2) RP-1664: First-in-class selective PLK4 inhibitor (Phase 1) Developing Next-Generation Precision Oncology Medicines Multiple clinical catalysts expe

  47. Slide 47: Insight that enriches. Precision that empowers.

    Insight that enriches. Precision that empowers. Corporate Presentation May 2024

Repare Therapeutics — Investor Presentation (May 2024) on 6ix